M1 Receptor Positive Allosteric Modulators for Selective Cognitive Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and cognitive disorders lack effective muscarinic M1 receptor modulators, with existing M1 PAMs not having been commercialized despite promising preclinical results, highlighting a need for novel and more effective compounds that can selectively modulate muscarinic M1 receptors without gastrointestinal side effects.
Innovation Solution
Development of compounds of formula (I), which are muscarinic M1 receptor positive allosteric modulators (M1 PAMs), specifically designed to target the less conserved allosteric binding site, potentially offering selective activation of the M1 receptor with minimal side effects and therapeutic benefits for cognitive disorders, including Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If M1 PAM compounds are developed to selectively activate muscarinic M1 receptors, then cognitive function enhancement and disease-modifying effects are improved, but gastrointestinal side effects may occur due to off-target activation of other muscarinic subtypes
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that confer selectivity for the M1 receptor subtype. The compounds contain a pyridine ring linked to a piperidine or morpholine core with specific substituents (R1-R6 groups) that create local molecular characteristics matching the M1 allosteric binding site, thereby achieving selective activation of M1 receptors while minimizing activation of other muscarinic subtypes in gastrointestinal tissues
Solution Approach 2:
The patent uses an allosteric binding site as an intermediary approach. Instead of directly competing at the orthosteric acetylcholine binding site (which is highly conserved across all muscarinic subtypes), the compounds bind to a distinct allosteric site on the M1 receptor. This intermediary binding mechanism allows selective modulation of M1 receptor activity without triggering off-target effects on other muscarinic subtypes, thereby reducing gastrointestinal side effects
2Reliability
If high selectivity for M1 receptor is achieved through allosteric binding site targeting, then therapeutic efficacy for cognitive disorders is improved, but compound structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a pyridine ring segment (providing aromatic character and hydrogen bonding capability), a central piperidine or morpholine segment (providing basic nitrogen and conformational flexibility), and variable substituent segments (R1-R6 groups) that fine-tune selectivity and pharmacokinetic properties. This segmented approach allows systematic optimization of selectivity without excessive overall complexity
Solution Approach 2:
The patent employs composite molecular structures combining heterocyclic rings (pyridine, piperidine, morpholine) with various aromatic and aliphatic substituents. These composite structures integrate multiple functional elements that work synergistically: the pyridine-piperidine/morpholine core provides M1-selective allosteric binding, while attached aromatic groups (phenyl, naphthyl, heteroaryl) and alkyl chains modulate lipophilicity, metabolic stability, and receptor affinity, achieving high selectivity through structured complexity rather than random complexity
Data Source
AI summary
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).